NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

$1.23
+0.06 (+5.13%)
(As of 04/22/2024 ET)
Today's Range
$1.16
$1.28
50-Day Range
$1.14
$1.78
52-Week Range
$0.53
$3.29
Volume
4,335 shs
Average Volume
63,931 shs
Market Capitalization
$20.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

RenovoRx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
591.1% Upside
$8.50 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of RenovoRx in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.97 out of 5 stars

Medical Sector

791st out of 910 stocks

Pharmaceutical Preparations Industry

367th out of 420 stocks

RNXT stock logo

About RenovoRx Stock (NASDAQ:RNXT)

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.

RNXT Stock Price History

RNXT Stock News Headlines

RenovoRx (NASDAQ:RNXT) Trading 5.1% Higher
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
RenovoRx announces key leadership promotions
RenovoRx annonce des promotions à des postes clés
RenovoRx Highlights Key Leadership Promotions
RenovoRx closes $6.1M private placement
RenovoRx Closes $6.1 Million Private Placement
RenovoRx Inc RNXT
Maxim Group Downgrades RenovoRx (RNXT)
RenovoRx GAAP EPS of -$0.13
See More Headlines
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/22/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RNXT
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$13.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+591.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-10,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.28) per share

Miscellaneous

Free Float
15,348,000
Market Cap
$20.75 million
Optionable
Not Optionable
Beta
1.04
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Ramtin Agah M.D. (Age 57)
    Founder, Chairman of Board & Chief Medical Officer
    Comp: $332.89k
  • Mr. Shaun R. Bagai (Age 47)
    CEO & Director
    Comp: $589.38k
  • Mr. Ronald B. Kocak CPA (Age 67)
    CGMA, VP, Controller & Principal Accounting Officer
  • Ms. Leesa Gentry (Age 54)
    Chief Clinical Officer

RNXT Stock Analysis - Frequently Asked Questions

Should I buy or sell RenovoRx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RNXT shares.
View RNXT analyst ratings
or view top-rated stocks.

What is RenovoRx's stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for RenovoRx's stock. Their RNXT share price targets range from $4.00 to $13.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 591.1% from the stock's current price.
View analysts price targets for RNXT
or view top-rated stocks among Wall Street analysts.

How have RNXT shares performed in 2024?

RenovoRx's stock was trading at $2.29 at the beginning of the year. Since then, RNXT shares have decreased by 46.3% and is now trading at $1.23.
View the best growth stocks for 2024 here
.

When is RenovoRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RNXT earnings forecast
.

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNXT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners